| Date | Title | Description | |
|---|---|---|---|
| 21 Feb 2023 | On business and financial situation | The Company releases the full year 2022 financial results presentation. | Download |
| 21 Feb 2023 | On business and financial situation | The Company releases the press release related to the full year 2022 financial results. | Download |
| 23 Nov 2022 | On business and financial situation | The Company releases the presentation related to its strategy update because of its 2022 Capital Markets Day | Download |
| 04 Nov 2022 | On business and financial situation | The Company releases the press release related to the first nine months of 2022 financial results | Download |
| 04 Nov 2022 | On business and financial situation | The Company releases the first nine months 2022 financial results presentation | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 18 Nov 2025 | On business and financial situation | The Company releases the press release in relation to the signing of the definitive collaboration agreement with Roche for the manufacture of a new medicine in development | Download |
| 02 Oct 2025 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the third quarter of 2025 | Download |
| 04 Jul 2025 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the second quarter of 2025 | Download |
| 03 Jul 2025 | Other relevant information | The Company informs about the dividends payment. | Download |
| 18 Jun 2025 | Announcement of general shareholders’ meeting | The Company reports on the resolutions adopted by the Ordinary General Shareholders' Meeting and by the Board of Directors. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 05 Oct 2017 | Contratos de liquidez y contrapartida | Liquidity contract: modification of transactions conducted from 11 July to 30 September 2017. | Download |
| 03 Oct 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted from 11 July to 30 September 2017 | Download |
| 07 Sep 2017 | Otros sobre negocio y situación financiera | The Company informs that commences the enoxaparin biosimilar marketing in Germany | Download |
| 26 Jul 2017 | Información sobre resultados | ROVI releases the presentation related to the 2017 first half results | Download |
| 26 Jul 2017 | Información sobre resultados | ROVI releases the presentation related to the 2017 first half results | Download |